To see this page, please, enable javaScript and styleSheets on your browser: Tools -> Internet Options ...
Reload !
Gene MDKTABLE OF CONTENTS / OPEN CLOSE ALL PARAGRAPHS
Summary back to top
Compact gene diagram back to top
562 supporting clones for gene MDK back to top
cDNA accession
Links to the sequence
Tissue

most 5' clones
in red
Match
mRNA
From bp
to bp
in mRNA
From bp
to bp
in accs.
Clone encodes
complete protein
(with AA variation)
Features Anomalies
detected by
AceView
Accession
match over
(% length)
Base differences
relative to genome
(% identity)
BU184807 melanotic melanoma, cell line, skin .a 1 to 505 1 to 505       505/889
(56 %)
13 diff
(98.6 %id)
BQ668643 epidermoid carcinoma, cell line, salivary gland .a 1 to 503 1 to 503       503/926
(54 %)
13 diff
(98.6 %id)
BQ668678 epidermoid carcinoma, cell line, salivary gland .a 1 to 673 1 to 680   tiling clone,   680/963
(70 %)
32 diff
(96.7 %id)
AK309963 Prostate .a 29 to 1885 1 to 1857 exact tiling clone,   1857/1857
(100 %)
1 diff
(100.0 %id)
DC383107 Prostate .a 29 to 558 1 to 530       530/530
(100 %)
1 diff
(99.9 %id)
BI519974 brain, medulla .a 31 to 766 1 to 747       745/825
(90 %)
12 diff
(98.6 %id)
TI_43964004   .a 31 to 766 58 to 804       745/882
(84 %)
16 diff
(98.2 %id)
AK308210 small intestine .a 156 to 1834 1 to 1678 R230A L231C tiling clone,   1678/1678
(100 %)
1 diff
(100.0 %id)
DT220418 brain .a 156 to 646 1 to 490       490/490
(100 %)
1 diff
(99.8 %id)
DC387806 small intestine .a 156 to 727 1 to 572       572/572
(100 %)
0 diff
(100 %id)
CN266396 embryonic stem cells, cell lines H1, H7, andH9 .a 170 to 561 84 to 475       392/475
(82 %)
9 diff
(98.2 %id)
CN266436 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 186 to 557 1 to 372       372/372
(100 %)
1 diff
(99.8 %id)
BM839270 Ascites, stomach .a 200 to 636 1 to 430       430/430
(100 %)
4 diff
(99.1 %id)
CN266404 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 205 to 673 1 to 469       469/470
(99 %)
0 diff
(100 %id)
BQ653612 hepatocellular carcinoma, cell line, Liver .a 219 to 673 1 to 455       455/1205
(37 %)
3 diff
(99.8 %id)
CN266462 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 230 to 820 1 to 591       591/591
(100 %)
0 diff
(100 %id)
TI_57197830   .a 305 to 908 32 to 637       606/637
(95 %)
12 diff
(98.2 %id)
BI820606 pooled brain, lung, testis .a 306 to 908 1 to 605       605/605
(100 %)
7 diff
(98.9 %id)
CN266424 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 310 to 748 1 to 439       439/439
(100 %)
0 diff
(100 %id)
AU126711   .a 312 to 788 2 to 481   capped   480/482
(99 %)
5 diff
(99.0 %id)
T50637 ovary .a 335 to 562 1 to 229       229/267
(85 %)
13 diff
(95.2 %id)
CN266400 embryonic stem cells, DMSO-treated H9 cellline .a 408 to 694 1 to 287       287/287
(100 %)
1 diff
(99.7 %id)
BP419708 small intestine .a 415 to 773 1 to 360     Submitted on the opposite strand 360/361
(99 %)
3 diff
(99.2 %id)
CN266406 embryonic stem cells, DMSO-treated H9 cellline .a 422 to 751 4 to 333       330/333
(99 %)
6 diff
(98.2 %id)
CN266454 embryonic stem cells, DMSO-treated H9 cellline .a 429 to 813 1 to 385       385/385
(100 %)
3 diff
(99.3 %id)
AA037265 senescent fibroblast .a 429 to 854 1 to 435       435/460
(94 %)
24 diff
(94.8 %id)
AW001140 colon, colonic mucosa from 3 patients with Crohn'sdisease .a 429 to 803 415 to 41       375/415
(90 %)
8 diff
(98.1 %id)
CN266474 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 431 to 835 1 to 406       406/407
(99 %)
4 diff
(99.1 %id)
W04805 lung .a 431 to 550 1 to 120       120/120
(100 %)
5 diff
(95.9 %id)
BF799202 colon_ins .a 433 to 747 338 to 24     Submitted on the opposite strand 315/338
(93 %)
2 diff
(99.5 %id)
CN266429 embryonic stem cells, DMSO-treated H9 cellline .a 435 to 755 1 to 321       321/321
(100 %)
0 diff
(100 %id)
CN266487 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 436 to 770 1 to 335       335/335
(100 %)
0 diff
(100 %id)
BM827021 Ascites, stomach .a 437 to 752 1 to 316       316/316
(100 %)
0 diff
(100 %id)
CN266421 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 441 to 875 1 to 435       435/435
(100 %)
0 diff
(100 %id)
CN266385 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .a 443 to 652 1 to 210       210/210
(100 %)
0 diff
(100 %id)
CN266486 embryonic stem cells, DMSO-treated H9 cellline .a 444 to 748 1 to 305       305/305
(100 %)
1 diff
(99.7 %id)
R72795 breast .a 452 to 674 1 to 220       220/260
(84 %)
17 diff
(93.5 %id)
CN266475 embryonic stem cells, DMSO-treated H9 cellline .a 474 to 861 1 to 389       389/389
(100 %)
1 diff
(99.8 %id)
BM760497 lymph node, stomach .a 506 to 750 1 to 245       245/245
(100 %)
1 diff
(99.6 %id)
AA155766 Pancreas .a 511 to 666 98 to 251       154/251
(61 %)
6 diff
(97.7 %id)
AA155768 Pancreas .a 511 to 666 98 to 251       154/251
(61 %)
6 diff
(97.7 %id)
AA444088 ovarian tumor, ovary .a 532 to 840 1 to 306       306/522
(58 %)
9 diff
(98.3 %id)
AA340127 brain .a 576 to 781 1 to 206       206/206
(100 %)
0 diff
(100 %id)
AA095477   .a 674 to 835 1 to 161       161/162
(99 %)
9 diff
(94.5 %id)
AA121965 Pancreas .a 723 to 872 1 to 151       151/151
(100 %)
1 diff
(99.4 %id)
CB215466 normal endometrium, late proliferativephase, cycle day 13, uterus .a 861 to 1511 1 to 650       650/650
(100 %)
1 diff
(99.9 %id)
BX349040 Placenta Cot 25-normalized .a 1051 to 1838 1 to 783       783/849
(92 %)
33 diff
(96.2 %id)
DT219727 brain .a 1057 to 1728 1 to 672       672/672
(100 %)
0 diff
(100 %id)
CN266533 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .a 1089 to 1627 19 to 559       541/559
(96 %)
6 diff
(99.0 %id)
TI_149292995   .a 1171 to 1886 792 to 82   AAA   711/791
(89 %)
25 diff
(96.9 %id)
AA121966 Pancreas .a 1417 to 1886 470 to 1       470/473
(99 %)
4 diff
(99.2 %id)
AI127036 heart .a 1494 to 1893 400 to 2       399/400
(99 %)
0 diff
(100 %id)
AI185816 lung .a 1494 to 1887 394 to 1       394/394
(100 %)
0 diff
(100 %id)
AW474443 serous papillary carcinoma, high grade, 2pooled tumors, uterus .a 1523 to 1886 364 to 1       364/364
(100 %)
4 diff
(99.0 %id)
AA443893 ovarian tumor, ovary .a 1554 to 1886 356 to 22   AAA   335/528
(63 %)
7 diff
(98.7 %id)
AI819736 2 pooled tumors (clear cell type), Kidney .a 1872 to 2193 1 to 323   tiling clone, Submitted on the opposite strand 323/323
(100 %)
8 diff
(97.6 %id)
AI285914 pooled .a 1886 to 2265 1 to 380   tiling clone, Submitted on the opposite strand 380/380
(100 %)
4 diff
(99.0 %id)
BM924518 pooled colon, kidney, stomach .b 1 to 959 1 to 973 F49S S50L R52D P53R G54V ... tiling clone,   973/1070
(90 %)
32 diff
(97.1 %id)
BY796308 eye .b 8 to 704 1 to 697       697/697
(100 %)
0 diff
(100 %id)
BQ647176 hepatocellular carcinoma, cell line, Liver .b 10 to 748 9 to 753       745/859
(86 %)
13 diff
(98.5 %id)
BE563428 adenocarcinoma, Pancreas .b 52 to 793 1 to 736       736/762
(96 %)
17 diff
(97.8 %id)
BQ225536 epithelioid carcinoma, Pancreas .b 86 to 931 1 to 862       862/865
(99 %)
23 diff
(97.4 %id)
CN266490 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .b 94 to 711 1 to 620       620/620
(100 %)
6 diff
(99.1 %id)
CN266466 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .b 113 to 682 1 to 571       571/571
(100 %)
2 diff
(99.7 %id)
BG622813 placenta .b 113 to 782 1 to 669       669/687
(97 %)
11 diff
(98.4 %id)
CN266369 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .b 126 to 822 1 to 697       697/697
(100 %)
1 diff
(99.9 %id)
CN266451 embryonic stem cells, DMSO-treated H9 cellline .b 127 to 782 1 to 656       656/656
(100 %)
7 diff
(99.0 %id)
BQ069753 brain, neuroblastoma, cell line .b 140 to 963 1 to 823   tiling clone, AAA   823/823
(100 %)
4 diff
(99.6 %id)
BQ070699 brain, neuroblastoma, cell line .b 140 to 966 1 to 848   tiling clone,   848/1076
(78 %)
33 diff
(97.0 %id)
BE260964 brain, neuroblastoma .b 153 to 835 1 to 680       680/680
(100 %)
12 diff
(98.3 %id)
BF206407 brain, neuroblastoma .b 157 to 893 1 to 731       731/984
(74 %)
23 diff
(97.7 %id)
CN266438 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .c 1 to 437 1 to 437   tiling clone,   437/437
(100 %)
3 diff
(99.4 %id)
BM887813 eye .c 12 to 528 1 to 520   AAA   520/521
(99 %)
7 diff
(98.7 %id)
BI914771 brain .c 23 to 586 1 to 565   tiling clone,   565/735
(76 %)
6 diff
(99.2 %id)
TI_57244108   .c 23 to 586 34 to 598       565/768
(73 %)
12 diff
(98.5 %id)
BM546345 ovary (pool of 3) .c 29 to 559 21 to 551       531/555
(95 %)
13 diff
(97.7 %id)
AL553751 placenta, Placenta Cot 25-normalized .c 36 to 914 1 to 880   tiling clone,   880/880
(100 %)
12 diff
(98.7 %id)
CN266456 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .c 37 to 543 1 to 507       507/507
(100 %)
1 diff
(99.9 %id)
BI198298 brain, neuroblastoma .c 39 to 527 1 to 497       497/783
(63 %)
24 diff
(97.0 %id)
BM798788 myeloma .c 39 to 370 1 to 332       332/332
(100 %)
0 diff
(100 %id)
BM809472 amelanotic melanoma, cell line, skin .c 40 to 394 1 to 354       354/1333
(26 %)
10 diff
(99.3 %id)
BM826761 stomach .c 41 to 439 1 to 399       399/399
(100 %)
0 diff
(100 %id)
BM852008 stomach .c 42 to 482 1 to 441       441/441
(100 %)
2 diff
(99.6 %id)
DB496226 hypothalamus .c 43 to 513 1 to 471       471/471
(100 %)
2 diff
(99.6 %id)
BM839872 myeloma .c 43 to 495 10 to 462       453/453
(100 %)
1 diff
(99.8 %id)
CN266365 embryonic stem cells, DMSO-treated H9 cellline .c 47 to 514 1 to 468       468/468
(100 %)
0 diff
(100 %id)
CN266389 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .c 47 to 405 1 to 364       362/364
(99 %)
5 diff
(98.7 %id)
TI_57177769   .c 48 to 586 28 to 576       549/836
(65 %)
26 diff
(96.9 %id)
BI766264 pooled lung and spleen .c 53 to 586 1 to 544       544/804
(67 %)
24 diff
(97.1 %id)
BQ233742 brain .c 56 to 903 1 to 863   tiling clone,   863/894
(96 %)
33 diff
(96.4 %id)
CN266489 embryonic stem cells, cell lines H1, H7, andH9 .c 67 to 548 1 to 483       483/483
(100 %)
6 diff
(98.8 %id)
CN266477 embryonic stem cells, DMSO-treated H9 cellline .c 73 to 559 1 to 487       487/487
(100 %)
3 diff
(99.4 %id)
CX760719 Blastocyst, pluripotent cell line derived fromblastocyst inner cell mass .c 83 to 563 1 to 481     Submitted on the opposite strand 481/706
(68 %)
1 diff
(99.9 %id)
CN266356 embryonic stem cells, cell lines H1, H7, andH9 .c 90 to 545 1 to 456       456/456
(100 %)
1 diff
(99.8 %id)
CN266376 embryonic stem cells, cell lines H1, H7, andH9 .d 1 to 451 4 to 454   tiling clone,   454/454
(100 %)
2 diff
(99.6 %id)
CR590366 neuroblastoma .d 15 to 1353 1 to 1339 exact tiling clone,   1339/1339
(100 %)
0 diff
(100 %id)
CN266379 embryonic stem cells, DMSO-treated H9 cellline .d 29 to 454 1 to 426       426/426
(100 %)
2 diff
(99.6 %id)
CN266461 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .d 43 to 570 1 to 528       528/528
(100 %)
0 diff
(100 %id)
AL516918 brain, neuroblastoma, neuroblastoma cells .d 53 to 734 35 to 712 D26X D95* fully sequenced,   678/712
(95 %)
10 diff
(98.6 %id)
BF688256 eye, normal pigmented retinal epithelium .d 649 to 1353 1 to 705       705/825
(85 %)
11 diff
(98.7 %id)
AL516917 brain, neuroblastoma, neuroblastoma cells .d 704 to 1346 638 to 8   fully sequenced,   631/638
(98 %)
3 diff
(99.6 %id)
CN278003 embryonic stem cells, DMSO-treated H9 cellline .e 1 to 540 1 to 540   tiling clone,   540/540
(100 %)
0 diff
(100 %id)
N31429 melanocyte .e 361 to 698 1 to 335   tiling clone,   335/365
(91 %)
18 diff
(95.1 %id)
N25317 melanocyte .e 793 to 865 73 to 1   tiling clone,   73/73
(100 %)
0 diff
(100 %id)
BE904189 epithelioid carcinoma, Pancreas .f 1 to 783 1 to 774 C52G Q104K G105A T106P L107* tiling clone,   776/857
(90 %)
28 diff
(96.8 %id)
CR601916 T cells (Jurkat cell line) Cot10-normalized .f 10 to 1035 1 to 1026 exact tiling clone,   1026/1026
(100 %)
0 diff
(100 %id)
BX346163   .f 10 to 589 1 to 580   fully sequenced,   580/580
(100 %)
2 diff
(99.7 %id)
BU860074 adenocarcinoma, cell line, breast .f 12 to 628 1 to 621       621/1060
(58 %)
11 diff
(99.0 %id)
CN266464 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .f 22 to 558 1 to 537       537/537
(100 %)
1 diff
(99.9 %id)
CN266471 embryonic stem cells, cell lines H1, H7, andH9 .f 22 to 280 1 to 259       259/259
(100 %)
0 diff
(100 %id)
CN266459 embryonic stem cells, DMSO-treated H9 cellline .f 23 to 500 1 to 479       479/479
(100 %)
1 diff
(99.8 %id)
CN277787 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .f 23 to 344 1 to 322       322/322
(100 %)
0 diff
(100 %id)
BQ070751 brain, neuroblastoma, cell line .f 102 to 727 1 to 627       627/1150
(54 %)
26 diff
(97.8 %id)
AU126531   .f 137 to 679 2 to 549   capped   548/548
(100 %)
13 diff
(97.7 %id)
BF983613 duodenal adenocarcinoma, cell line, small intestine .f 190 to 912 1 to 721 K138T K140N K142T D143G     721/1125
(64 %)
25 diff
(97.8 %id)
BX346162   .f 528 to 1024 509 to 12   fully sequenced,   498/509
(97 %)
2 diff
(99.7 %id)
CN266447 embryonic stem cells, DMSO-treated H9 cellline .g 1 to 742 1 to 743 exact tiling clone,   743/743
(100 %)
6 diff
(99.2 %id)
NM_001012333.1   .g 6 to 901 1 to 896 exact RefSeq, AAA   896/896
(100 %)
0 diff
(100 %id)
AA428047   .g 9 to 470 1 to 457   fully sequenced,   457/457
(100 %)
10 diff
(97.9 %id)
BM016739 astrocytoma grade IV, cell line, brain .g 19 to 732 1 to 714 K108N K109E A110G R111A Y112L ...     714/717
(99 %)
14 diff
(98.1 %id)
TI_59386973   .g 20 to 732 99 to 811 K108N K109E A110G R111A Y112L ...     713/716
(99 %)
13 diff
(98.2 %id)
CN266346 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .g 43 to 720 1 to 677 exact     677/677
(100 %)
3 diff
(99.6 %id)
CN266411 embryonic stem cells, cell lines H1, H7, andH9 .g 94 to 778 1 to 686 exact tiling clone,   686/686
(100 %)
3 diff
(99.6 %id)
AA427949   .g 440 to 878 442 to 5   tiling clone, fully sequenced,   438/442
(99 %)
0 diff
(100 %id)
NM_002391.3   .h 1 to 853 1 to 853 exact RefSeq, AAA   853/853
(100 %)
0 diff
(100 %id)
BM842627 lymph node, stomach .h 1 to 581 1 to 580 exact     580/580
(100 %)
2 diff
(99.7 %id)
BM761575 myeloma .h 1 to 232 1 to 232       232/232
(100 %)
0 diff
(100 %id)
BM849536 myeloma .h 1 to 703 1 to 703 exact tiling clone,   703/703
(100 %)
0 diff
(100 %id)
BM785265 myeloma .h 1 to 575 1 to 574 Q2A     574/574
(100 %)
1 diff
(99.9 %id)
BM761836 lymph node, stomach .h 2 to 208 1 to 205       205/205
(100 %)
3 diff
(98.6 %id)
BM924222 pooled colon, kidney, stomach .h 4 to 835 19 to 852 exact     834/881
(94 %)
14 diff
(98.5 %id)
CD050944 embryonic trophoblasts, made from WA01 stemcells .h 5 to 799 20 to 821 exact AAA   802/862
(93 %)
17 diff
(98.1 %id)
BM913383 amelanotic melanoma, cell line, skin .h 5 to 800 15 to 821 exact     807/1067
(75 %)
34 diff
(96.9 %id)
BM914702 amelanotic melanoma, cell line, skin .h 5 to 594 1 to 592 exact     592/1281
(46 %)
18 diff
(98.6 %id)
CN266378 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 7 to 737 1 to 733 exact     733/733
(100 %)
3 diff
(99.6 %id)
BQ787789 insulinoma, Pancreas .h 7 to 526 1 to 520 exact fully sequenced,   520/520
(100 %)
5 diff
(99.1 %id)
BQ961868 epithelioid carcinoma cell line, Pancreas .h 7 to 835 1 to 843 A22P     843/940
(89 %)
28 diff
(97.1 %id)
CR602072 neuroblastoma .h 8 to 835 1 to 828 exact     828/828
(100 %)
0 diff
(100 %id)
BM423459 amelanotic melanoma, cell line, skin .h 11 to 830 1 to 832 exact AAA   832/832
(100 %)
17 diff
(98.0 %id)
BX416313 neuroblastoma .h 12 to 835 6 to 828 C37F K85X Y86F C94F D95Y     823/829
(99 %)
20 diff
(97.6 %id)
BM913540 amelanotic melanoma, cell line, skin .h 13 to 828 1 to 814 exact AAA   814/814
(100 %)
2 diff
(99.8 %id)
BM821995 stomach .h 13 to 221 1 to 208       208/208
(100 %)
1 diff
(99.6 %id)
BG750759 eye, normal pigmented retinal epithelium .h 14 to 671 1 to 660 K142T D143R     660/662
(99 %)
4 diff
(99.4 %id)
BG830977 epithelioid carcinoma cell line, Pancreas .h 14 to 798 1 to 781 P33R S35A E36S C37A A38L ...     781/810
(96 %)
11 diff
(98.7 %id)
BM423353 amelanotic melanoma, cell line, skin .h 14 to 828 1 to 815 exact AAA   815/815
(100 %)
4 diff
(99.6 %id)
CN266362 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 15 to 657 9 to 651 exact     643/651
(98 %)
11 diff
(98.4 %id)
CN266425 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 15 to 636 1 to 625 exact     625/625
(100 %)
5 diff
(99.2 %id)
BQ069097 brain, neuroblastoma, cell line .h 15 to 828 36 to 849 exact     814/1045
(77 %)
8 diff
(99.3 %id)
BM750349 stomach .h 15 to 565 1 to 551 exact     551/551
(100 %)
0 diff
(100 %id)
AA232437 brain, neuroepithelial cells .h 16 to 358 1 to 341       341/341
(100 %)
9 diff
(97.4 %id)
BM782080 myeloma .h 16 to 520 1 to 505       505/505
(100 %)
2 diff
(99.7 %id)
BM849847 myeloma .h 16 to 520 1 to 505       505/505
(100 %)
0 diff
(100 %id)
BM789630 stomach .h 16 to 635 1 to 620 exact     620/620
(100 %)
0 diff
(100 %id)
BM790596 stomach .h 16 to 657 1 to 642 Q64H     642/642
(100 %)
1 diff
(99.9 %id)
BM850479 stomach .h 16 to 703 1 to 688 exact     688/692
(99 %)
4 diff
(99.5 %id)
CN266483 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 17 to 718 1 to 702 exact     702/702
(100 %)
2 diff
(99.8 %id)
BM781843 myeloma .h 17 to 570 1 to 554 K101X     554/554
(100 %)
1 diff
(99.9 %id)
BM785320 stomach .h 17 to 597 1 to 581 exact     581/581
(100 %)
1 diff
(99.9 %id)
BM790202 stomach .h 17 to 635 1 to 621 K133X     621/621
(100 %)
3 diff
(99.6 %id)
BM850649 stomach .h 17 to 635 1 to 619 exact     619/619
(100 %)
1 diff
(99.9 %id)
CD049399 embryonic stem cells, WA01, passage 38 .h 18 to 829 23 to 836 K23R K135* tiling clone, AAA   814/836
(97 %)
11 diff
(98.7 %id)
CN266452 embryonic stem cells, DMSO-treated H9 cellline .h 19 to 704 1 to 686 exact     686/686
(100 %)
1 diff
(99.9 %id)
BM760397 lymph node, stomach .h 20 to 521 1 to 502       502/502
(100 %)
0 diff
(100 %id)
CN266368 embryonic stem cells, DMSO-treated H9 cellline .h 22 to 769 1 to 748 exact     748/748
(100 %)
5 diff
(99.4 %id)
TI_149285949   .h 23 to 828 882 to 85 R4X F6S L7S L8S L9H ... AAA   798/804
(99 %)
14 diff
(98.3 %id)
BU783346 insulinoma, Pancreas .h 25 to 520 1 to 496       496/496
(100 %)
4 diff
(99.2 %id)
CN266399 embryonic stem cells, cell lines H1, H7, andH9 .h 28 to 658 13 to 644 S35E E36R C37V A38R E39*     632/644
(98 %)
7 diff
(99.0 %id)
CN266460 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 28 to 566 1 to 539 exact     539/539
(100 %)
1 diff
(99.9 %id)
BU184627 leiomyosarcoma, uterus .h 28 to 783 35 to 804 exact     770/926
(83 %)
34 diff
(96.4 %id)
BG830798 epithelioid carcinoma cell line, Pancreas .h 29 to 713 1 to 684 exact     684/684
(100 %)
6 diff
(99.2 %id)
BQ307873 breast .h 30 to 292 37 to 299       263/299
(87 %)
19 diff
(93.7 %id)
CN266343 embryonic stem cells, DMSO-treated H9 cellline .h 30 to 747 1 to 719 exact     719/719
(100 %)
3 diff
(99.6 %id)
CR614410 Neuroblastoma Cot 25-normalized .h 30 to 835 1 to 806 exact     806/806
(100 %)
0 diff
(100 %id)
AL528378 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .h 30 to 835 1 to 804 C37F C45A T46P S48A S49A ...     804/805
(99 %)
11 diff
(98.7 %id)
BI523831 pooled lung and spleen .h 30 to 840 1 to 817 exact     817/884
(92 %)
14 diff
(98.5 %id)
TI_44159426   .h 30 to 840 30 to 846 exact     817/913
(89 %)
20 diff
(97.9 %id)
CN266408 embryonic stem cells, DMSO-treated H9 cellline .h 31 to 590 1 to 560 exact     560/560
(100 %)
0 diff
(100 %id)
CN266431 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 31 to 566 1 to 536 exact     536/536
(100 %)
4 diff
(99.3 %id)
BQ932417 epidermoid carcinoma, cell line, lung .h 32 to 802 1 to 791 C94G C126L T127H K129Q T130D ...     791/998
(79 %)
30 diff
(97.0 %id)
BQ955533 epidermoid carcinoma, cell line, lung .h 32 to 830 1 to 807 exact AAA   807/807
(100 %)
13 diff
(98.4 %id)
BQ307332 breast .h 33 to 312 16 to 292       277/292
(94 %)
21 diff
(92.9 %id)
CD389765 embryonic trophoblasts, made from WA01 stemcells .h 36 to 835 24 to 825 G92V A93R C94V D95M G97A ... AAA   802/901
(89 %)
16 diff
(98.3 %id)
CD387595 embryonic trophoblasts, made from WA01 stemcells .h 37 to 828 11 to 802 exact AAA   792/802
(98 %)
8 diff
(99.1 %id)
CN266361 embryonic stem cells, DMSO-treated H9 cellline .h 37 to 779 1 to 743 exact     743/743
(100 %)
5 diff
(99.4 %id)
CN266375 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 37 to 722 1 to 686 exact     686/686
(100 %)
2 diff
(99.8 %id)
AA075883   .h 37 to 387 1 to 348   fully sequenced,   348/348
(100 %)
29 diff
(91.7 %id)
AW163233 brain, frontal lobe .h 37 to 431 1 to 396   fully sequenced,   396/396
(100 %)
1 diff
(99.8 %id)
BU179690 ductal carcinoma, cell line, Pancreas .h 39 to 831 1 to 796 exact AAA   796/796
(100 %)
8 diff
(99.0 %id)
CB109442 Liver .h 41 to 287 1 to 247       247/247
(100 %)
4 diff
(98.4 %id)
AU129491   .h 42 to 376 2 to 334   fully sequenced, capped   333/333
(100 %)
4 diff
(98.8 %id)
CN266444 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 43 to 699 1 to 656 exact     656/656
(100 %)
5 diff
(99.3 %id)
AU126631   .h 43 to 537 2 to 495 K137R K140X G141E K142R D143I capped   494/495
(99 %)
9 diff
(98.2 %id)
CN266367 embryonic stem cells, DMSO-treated H9 cellline .h 44 to 667 9 to 632 exact     624/632
(98 %)
8 diff
(98.8 %id)
CN266479 embryonic stem cells, DMSO-treated H9 cellline .h 44 to 398 1 to 355       355/355
(100 %)
0 diff
(100 %id)
BQ689983 ductal carcinoma, cell line, Pancreas .h 44 to 828 1 to 785 exact AAA   785/785
(100 %)
1 diff
(99.9 %id)
BQ889499 ductal carcinoma, cell line, Pancreas .h 44 to 835 1 to 800 exact     800/939
(85 %)
18 diff
(98.1 %id)
CB120838 cervix, Uterine .h 45 to 370 1 to 326       326/326
(100 %)
3 diff
(99.1 %id)
CD050086 embryonic trophoblasts, made from WA01 stemcells .h 45 to 835 26 to 819 exact AAA   794/881
(90 %)
16 diff
(98.2 %id)
CD176858 embryonic trophoblasts, made from WA01 stemcells .h 45 to 831 19 to 805 exact AAA   787/805
(97 %)
9 diff
(98.9 %id)
CN266432 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 45 to 546 1 to 502 exact     502/502
(100 %)
5 diff
(99.1 %id)
AL697846 human skeletal muscle .h 45 to 830 1 to 793 F56L R57H AAA   793/793
(100 %)
12 diff
(98.5 %id)
BP249594 Kidney .h 45 to 449 1 to 405       405/408
(99 %)
4 diff
(99.1 %id)
BM773261 Ascites, stomach .h 45 to 441 1 to 397       397/397
(100 %)
0 diff
(100 %id)
BM782137 myeloma .h 45 to 580 1 to 536 exact     536/536
(100 %)
0 diff
(100 %id)
BP374141 umbilical cord .h 45 to 625 1 to 581 exact     581/581
(100 %)
0 diff
(100 %id)
CN266348 embryonic stem cells, cell lines H1, H7, andH9 .h 46 to 554 1 to 509 G5V     509/509
(100 %)
5 diff
(99.1 %id)
CN266455 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 46 to 703 1 to 658 exact     658/658
(100 %)
1 diff
(99.9 %id)
AL523055 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .h 46 to 835 40 to 826 H3P K24X K50Q K78X K85X ...     787/827
(95 %)
20 diff
(97.6 %id)
AU126400   .h 46 to 521 2 to 477   capped   476/486
(97 %)
11 diff
(97.8 %id)
AU126743   .h 46 to 595 2 to 551 exact capped   550/552
(99 %)
14 diff
(97.5 %id)
AU126776   .h 46 to 585 2 to 548 G139R K140G G141R K142E D143R capped   547/548
(99 %)
18 diff
(96.8 %id)
AU129753   .h 46 to 833 2 to 797 exact fully sequenced, capped   796/796
(100 %)
16 diff
(98.0 %id)
BM789652 stomach .h 46 to 704 1 to 659 exact     659/659
(100 %)
0 diff
(100 %id)
BM791426 stomach .h 46 to 587 1 to 542 exact     542/542
(100 %)
0 diff
(100 %id)
BM850825 stomach .h 46 to 282 1 to 237       237/240
(98 %)
1 diff
(99.6 %id)
BM850609 stomach .h 46 to 575 1 to 530 D83H K129N     530/530
(100 %)
4 diff
(99.3 %id)
CN266384 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 47 to 658 1 to 612 exact     612/612
(100 %)
4 diff
(99.4 %id)
CN266402 embryonic stem cells, DMSO-treated H9 cellline .h 47 to 828 1 to 783 exact     783/784
(99 %)
5 diff
(99.4 %id)
CN266403 embryonic stem cells, DMSO-treated H9 cellline .h 47 to 379 1 to 333       333/333
(100 %)
3 diff
(99.1 %id)
BF032696 adenocarcinoma, ovary .h 47 to 826 1 to 769 A20D V21G A22R K23Q K25E ...     769/811
(94 %)
40 diff
(95.1 %id)
BE908959 epithelioid carcinoma, Pancreas .h 47 to 835 1 to 790 exact     790/828
(95 %)
33 diff
(96.1 %id)
CB111177 Liver .h 47 to 413 1 to 367       367/367
(100 %)
0 diff
(100 %id)
CN266465 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 48 to 472 1 to 426       426/426
(100 %)
1 diff
(99.8 %id)
BG683279 brain, neuroblastoma, cell line .h 48 to 684 1 to 637 exact     637/639
(99 %)
2 diff
(99.7 %id)
CN266427 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 49 to 672 1 to 624 exact     624/624
(100 %)
3 diff
(99.6 %id)
CN266453 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 49 to 680 2 to 632 exact     631/632
(99 %)
5 diff
(99.3 %id)
CN266469 embryonic stem cells, cell lines H1, H7, andH9 .h 49 to 413 12 to 376       365/376
(97 %)
6 diff
(98.5 %id)
BF033796 adenocarcinoma, ovary .h 50 to 825 1 to 772 K24I K25E D26R K27* AAA   772/772
(100 %)
40 diff
(94.9 %id)
BE908776 epithelioid carcinoma, Pancreas .h 50 to 636 1 to 587 K30T K140N G141A K142Q     587/588
(99 %)
5 diff
(99.2 %id)
CN266357 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 51 to 751 10 to 710 exact     701/710
(98 %)
7 diff
(99.1 %id)
CN266416 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 52 to 691 1 to 640 exact     640/640
(100 %)
0 diff
(100 %id)
BM730021 insulinoma, Pancreas .h 52 to 414 8 to 370       363/370
(98 %)
9 diff
(97.6 %id)
CN266347 embryonic stem cells, DMSO-treated H9 cellline .h 53 to 416 1 to 364       364/364
(100 %)
0 diff
(100 %id)
CN266382 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 53 to 694 1 to 642 exact     642/642
(100 %)
0 diff
(100 %id)
CR624204 Neuroblastoma Cot 25-normalized .h 53 to 835 1 to 783 exact     783/783
(100 %)
0 diff
(100 %id)
AL523011 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .h 53 to 774 726 to 1 L12P A13R L14P L15X A16G ...     726/726
(100 %)
28 diff
(96.2 %id)
AL523012 brain, neuroblastoma cells, Neuroblastoma Cot 25-normalized .h 53 to 827 1 to 774 L17P D95E Y112N     774/774
(100 %)
10 diff
(98.8 %id)
DN994951 brain, whole brain .h 54 to 663 1 to 610 exact     610/610
(100 %)
4 diff
(99.4 %id)
AU126752   .h 55 to 601 2 to 548 K140X capped   547/547
(100 %)
8 diff
(98.6 %id)
AA364687 pineal body .h 56 to 355 1 to 300       300/301
(99 %)
3 diff
(99.1 %id)
BC011704 Uterus, endometrium adenocarcinoma .h 56 to 828 1 to 773 exact available from MGC, AAA   773/773
(100 %)
0 diff
(100 %id)
CN266374 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 56 to 827 1 to 771 exact     771/771
(100 %)
2 diff
(99.8 %id)
CN266409 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 56 to 787 1 to 734 exact     734/734
(100 %)
3 diff
(99.6 %id)
BG339806 leiomyosarcoma cell line, uterus .h 56 to 685 1 to 630 C126X     630/957
(65 %)
4 diff
(99.6 %id)
CN266364 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 57 to 692 1 to 636 exact     636/636
(100 %)
1 diff
(99.9 %id)
CN266457 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 57 to 587 1 to 531 D26N     531/531
(100 %)
3 diff
(99.5 %id)
CN266481 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .h 57 to 726 11 to 681 exact     671/681
(98 %)
8 diff
(98.9 %id)
CA942334 Pancreas, Purified pancreatic islet .h 59 to 528 1 to 470 exact fully sequenced,   470/470
(100 %)
0 diff
(100 %id)
BU557038 ovary, teratocarcinoma, cell line .h 59 to 830 1 to 775 exact AAA   775/775
(100 %)
5 diff
(99.4 %id)
BE312284 brain, neuroblastoma .h 61 to 758 1 to 708 K138T K140N D143G     708/775
(91 %)
28 diff
(96.4 %id)
BF033808 adenocarcinoma, ovary .h 62 to 821 1 to 765 L15S A16G L17A T18H S19L ...     729/766
(95 %)
47 diff
(93.9 %id)
BE736100 adenocarcinoma, Pancreas .h 63 to 751 1 to 678 C126L T127H K129Q T130R K131P ... AAA   674/739
(91 %)
27 diff
(96.4 %id)
BM830289 lymph node, stomach .h 64 to 402 1 to 340       340/340
(100 %)
9 diff
(97.4 %id)
CN266439 embryonic stem cells, DMSO-treated H9 cellline .h 66 to 691 1 to 627 exact     627/627
(100 %)
5 diff
(99.3 %id)
CN266448 embryonic stem cells, DMSO-treated H9 cellline .h 67 to 739 1 to 674 exact     674/685
(98 %)
10 diff
(98.6 %id)
X55110 brain .h 67 to 853 1 to 786 exact tiling clone, AAA   786/786
(100 %)
3 diff
(99.7 %id)
CN266349 embryonic stem cells, DMSO-treated H9 cellline .h 71 to 714 1 to 644 exact     644/644
(100 %)
0 diff
(100 %id)
CN266410 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 71 to 711 9 to 653 exact     645/653
(98 %)
5 diff
(99.3 %id)
CN266412 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 71 to 685 1 to 616 exact     616/616
(100 %)
4 diff
(99.4 %id)
CN266470 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 71 to 258 10 to 197       188/197
(95 %)
6 diff
(97.0 %id)
CN266480 embryonic stem cells, DMSO-treated H9 cellline .h 71 to 406 1 to 336       336/336
(100 %)
0 diff
(100 %id)
CN266417 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 72 to 572 1 to 502 S35Q E36R C37V A38R E39*     502/502
(100 %)
3 diff
(99.5 %id)
CN266422 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 72 to 827 1 to 753 exact     753/753
(100 %)
5 diff
(99.4 %id)
CD105980 brain, Pituitary .h 72 to 835 1 to 764 exact     764/792
(96 %)
4 diff
(99.5 %id)
BE294834 muscle, rhabdomyosarcoma .h 74 to 595 1 to 523 R57L E58R T60H C61L G62R ...     523/523
(100 %)
1 diff
(99.9 %id)
CN266415 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 75 to 322 1 to 248       248/248
(100 %)
0 diff
(100 %id)
BP421157 small intestine .h 75 to 585 1 to 511 exact   Submitted on the opposite strand 511/511
(100 %)
1 diff
(99.9 %id)
BE379029 endometrium, adenocarcinoma cell line, uterus .h 75 to 826 1 to 754 exact     754/754
(100 %)
15 diff
(98.1 %id)
BF036785 adenocarcinoma, ovary .h 75 to 737 1 to 664 C52A G53A V54W G55V F56S ...     664/666
(99 %)
12 diff
(98.2 %id)
CN266383 embryonic stem cells, DMSO-treated H9 cellline .h 77 to 415 1 to 339       339/339
(100 %)
0 diff
(100 %id)
CN266350 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 825 1 to 750 exact     750/750
(100 %)
3 diff
(99.6 %id)
CN266355 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 318 1 to 241       241/241
(100 %)
1 diff
(99.6 %id)
CN266372 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 828 1 to 754 R69L AAA   754/754
(100 %)
5 diff
(99.4 %id)
CN266391 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 673 1 to 596 exact     596/596
(100 %)
1 diff
(99.9 %id)
CN266413 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 395 1 to 318       318/318
(100 %)
1 diff
(99.7 %id)
CN266426 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 787 1 to 709 exact     709/714
(99 %)
2 diff
(99.8 %id)
CN266435 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 709 1 to 634 exact     634/634
(100 %)
7 diff
(98.9 %id)
CN266441 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 603 1 to 526 exact     526/526
(100 %)
2 diff
(99.7 %id)
CN266446 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 634 1 to 557 exact     557/557
(100 %)
0 diff
(100 %id)
CN266458 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 500 1 to 423       423/423
(100 %)
0 diff
(100 %id)
CN266467 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 683 1 to 606 exact     606/606
(100 %)
0 diff
(100 %id)
CN266472 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 674 1 to 597 exact     597/597
(100 %)
0 diff
(100 %id)
CN266484 embryonic stem cells, DMSO-treated H9 cellline .h 78 to 554 1 to 477 exact     477/477
(100 %)
1 diff
(99.8 %id)
CN266492 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 78 to 657 1 to 580 exact     580/580
(100 %)
1 diff
(99.9 %id)
CN266370 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 81 to 631 1 to 551 exact     551/551
(100 %)
0 diff
(100 %id)
BE315082 adenocarcinoma cell line, ovary .h 81 to 715 1 to 636 K138N G139R K140E D143G     636/637
(99 %)
9 diff
(98.6 %id)
BQ277681 ovary, teratocarcinoma, cell line .h 81 to 828 1 to 748 exact AAA   748/748
(100 %)
5 diff
(99.4 %id)
CN266419 embryonic stem cells, DMSO-treated H9 cellline .h 83 to 741 1 to 660 exact     660/660
(100 %)
2 diff
(99.7 %id)
CN266366 embryonic stem cells, DMSO-treated H9 cellline .h 86 to 742 1 to 658 exact     658/658
(100 %)
2 diff
(99.7 %id)
CN266345 embryonic stem cells, DMSO-treated H9 cellline .h 87 to 463 1 to 377       377/377
(100 %)
0 diff
(100 %id)
CN266351 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 87 to 532 1 to 446 exact     446/446
(100 %)
0 diff
(100 %id)
CN266373 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .h 87 to 773 1 to 688 exact     688/688
(100 %)
1 diff
(99.9 %id)
AA069239 Pancreas .h 88 to 272 1 to 190       190/190
(100 %)
11 diff
(94.3 %id)
AU151595   .h 346 to 828 479 to 1   fully sequenced,   479/479
(100 %)
7 diff
(98.6 %id)
AA071541   .h 373 to 828 460 to 1   fully sequenced,   460/460
(100 %)
6 diff
(98.7 %id)
AW157228 brain, frontal lobe .h 401 to 835 436 to 2   fully sequenced,   435/436
(99 %)
0 diff
(100 %id)
BQ787607 insulinoma, Pancreas .h 467 to 828 378 to 17   fully sequenced, AAA   362/362
(100 %)
0 diff
(100 %id)
CA867040 Pancreas, Purified pancreatic islet .h 467 to 827 361 to 1   fully sequenced,   361/361
(100 %)
0 diff
(100 %id)
AA232438 brain, neuroepithelial cells .h 496 to 695 203 to 1       203/233
(87 %)
14 diff
(94.0 %id)
AA069147 Pancreas .h 534 to 828 299 to 1       299/299
(100 %)
6 diff
(98.0 %id)
AU151827   .h 571 to 828 258 to 1   fully sequenced,   258/258
(100 %)
1 diff
(99.7 %id)
AK130889 umbilical cord .i 1 to 959 1 to 959 exact tiling clone, available from FLJ,   959/959
(100 %)
0 diff
(100 %id)
NM_001012334.1   .i 1 to 984 1 to 984 exact RefSeq, AAA   984/984
(100 %)
0 diff
(100 %id)
BP271152 small intestine .i 140 to 616 1 to 477       477/484
(98 %)
2 diff
(99.6 %id)
CN266478 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 213 to 958 1 to 747 exact     747/747
(100 %)
6 diff
(99.2 %id)
BE905304 epithelioid carcinoma, Pancreas .i 217 to 926 1 to 711 exact     711/748
(95 %)
18 diff
(97.6 %id)
BE907027 epithelioid carcinoma, Pancreas .i 217 to 894 1 to 680 exact     680/680
(100 %)
16 diff
(97.7 %id)
BG829436 epithelioid carcinoma cell line, Pancreas .i 220 to 966 1 to 745 V72C C74A N75T W76G K77R ...     745/779
(95 %)
13 diff
(98.4 %id)
BX353467 Neuroblastoma Cot 25-normalized .i 221 to 966 1 to 746 exact     746/746
(100 %)
0 diff
(100 %id)
CN266380 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 222 to 855 7 to 640 exact     634/640
(99 %)
0 diff
(100 %id)
CN266390 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 222 to 791 7 to 576 exact     570/576
(98 %)
1 diff
(99.9 %id)
CN266395 embryonic stem cells, DMSO-treated H9 cellline .i 222 to 818 7 to 603 exact     597/603
(99 %)
0 diff
(100 %id)
CN266418 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .i 222 to 814 1 to 595 L8R C94V D95*     595/595
(100 %)
3 diff
(99.5 %id)
AI936124 normal prostate, Prostate .i 222 to 961 743 to 4 R4E G5X L7S L8S L9S ...     740/760
(97 %)
15 diff
(98.1 %id)
BE881260 large cell carcinoma, undifferentiated, lung .i 222 to 952 1 to 728 F6V     728/730
(99 %)
17 diff
(97.7 %id)
BU844935 ovary, teratocarcinoma, cell line .i 222 to 982 2 to 762 exact AAA   761/762
(99 %)
0 diff
(100 %id)
BU554130 ovary, teratocarcinoma, cell line .i 222 to 959 57 to 795 R4* AAA   739/795
(92 %)
10 diff
(98.8 %id)
CV028369 mixed .i 223 to 653 1 to 431       431/601
(71 %)
7 diff
(98.9 %id)
M69148 Kidney .i 223 to 783 1 to 561 exact     561/562
(99 %)
1 diff
(99.9 %id)
CN266398 embryonic stem cells, DMSO-treated H9 cellline .i 224 to 909 1 to 687       687/687
(100 %)
2 diff
(99.8 %id)
BE048096 brain, tumor, 5 pooled (see description) .i 226 to 704 1 to 479       479/479
(100 %)
0 diff
(100 %id)
CN266430 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 227 to 727 1 to 501       501/503
(99 %)
3 diff
(99.5 %id)
BF035189 adenocarcinoma, ovary .i 227 to 797 1 to 585       585/1077
(54 %)
25 diff
(97.7 %id)
CN266449 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 228 to 835 1 to 608       608/615
(98 %)
1 diff
(99.9 %id)
AA126127   .i 228 to 658 1 to 432   fully sequenced,   432/432
(100 %)
9 diff
(98.0 %id)
BG753264 eye, normal pigmented retinal epithelium .i 230 to 883 1 to 654       654/655
(99 %)
2 diff
(99.7 %id)
CN266360 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 232 to 960 1 to 730       730/730
(100 %)
2 diff
(99.8 %id)
CN266440 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 234 to 640 1 to 407       407/407
(100 %)
2 diff
(99.6 %id)
CN266442 embryonic stem cells, cell lines H1, H7, andH9 .i 234 to 817 1 to 584       584/587
(99 %)
4 diff
(99.4 %id)
CN266358 embryonic stem cells, DMSO-treated H9 cellline .i 235 to 705 1 to 470       470/470
(100 %)
3 diff
(99.4 %id)
CN266393 embryonic stem cells, DMSO-treated H9 cellline .i 235 to 648 1 to 414       414/414
(100 %)
1 diff
(99.8 %id)
CN266420 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 235 to 709 1 to 475       475/475
(100 %)
0 diff
(100 %id)
CN266482 embryonic stem cells, DMSO-treated H9 cellline .i 235 to 654 25 to 444       420/444
(94 %)
6 diff
(98.7 %id)
CN266485 embryonic stem cells, DMSO-treated H9 cellline .i 235 to 699 1 to 466       466/466
(100 %)
1 diff
(99.8 %id)
CN266401 embryonic stem cells, DMSO-treated H9 cellline .i 236 to 809 1 to 574       574/574
(100 %)
1 diff
(99.9 %id)
CN266450 embryonic stem cells, DMSO-treated H9 cellline .i 237 to 697 1 to 461       461/465
(99 %)
2 diff
(99.6 %id)
CN266387 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 238 to 650 1 to 413       413/413
(100 %)
0 diff
(100 %id)
BQ268091 insulinoma, Pancreas .i 240 to 659 1 to 420   fully sequenced,   420/420
(100 %)
5 diff
(98.9 %id)
TI_149286042   .i 241 to 959 811 to 95   AAA   717/791
(90 %)
19 diff
(97.6 %id)
BI524069 pooled lung and spleen .i 242 to 910 90 to 762       673/762
(88 %)
11 diff
(98.6 %id)
TI_44159952   .i 242 to 910 123 to 795       673/795
(84 %)
11 diff
(98.7 %id)
CN266392 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 256 to 958 1 to 704       704/704
(100 %)
2 diff
(99.8 %id)
BF684205 leiomyosarcoma cell line, uterus .i 256 to 988 1 to 730       730/855
(85 %)
14 diff
(98.4 %id)
CN266397 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 258 to 886 1 to 629       629/629
(100 %)
3 diff
(99.6 %id)
CN266423 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 265 to 945 1 to 681       681/681
(100 %)
0 diff
(100 %id)
CN266468 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 267 to 957 1 to 691       691/691
(100 %)
2 diff
(99.8 %id)
BM711194 eye, fetal eyes .i 267 to 497 9 to 239   fully sequenced,   231/239
(96 %)
7 diff
(97.1 %id)
BU626178 cell lines, Enchondroma .i 272 to 959 705 to 19   AAA   687/687
(100 %)
1 diff
(99.9 %id)
CN266437 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 288 to 720 4 to 436       433/436
(99 %)
0 diff
(100 %id)
AL536136 brain, fetal brain .i 296 to 966 1 to 670       670/671
(99 %)
5 diff
(99.3 %id)
BX395389 Neuroblastoma Cot 50-normalized .i 297 to 966 1 to 668       668/669
(99 %)
29 diff
(95.7 %id)
CD673196 eye, Iris .i 297 to 655 105 to 463       359/463
(77 %)
9 diff
(98.1 %id)
AA846556 parathyroid gland, parathyroid tumor .i 297 to 959 676 to 12   AAA   665/684
(97 %)
25 diff
(96.4 %id)
AI246564 pharynx, squamous cell carcinoma .i 297 to 961 663 to 1       663/707
(93 %)
10 diff
(98.6 %id)
TI_149285220   .i 297 to 959 753 to 91   AAA   663/1105
(60 %)
17 diff
(98.5 %id)
TI_149288519   .i 297 to 960 712 to 50   AAA   663/687
(96 %)
15 diff
(97.9 %id)
TI_149291693   .i 297 to 959 738 to 83   AAA   656/694
(94 %)
8 diff
(98.9 %id)
AW167783 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 299 to 959 659 to 1       659/659
(100 %)
20 diff
(97.0 %id)
BM760043 lymph node, stomach .i 299 to 805 1 to 509       509/509
(100 %)
5 diff
(99.1 %id)
BM760288 lymph node, stomach .i 299 to 887 1 to 589       589/589
(100 %)
0 diff
(100 %id)
BM841344 lymph node, stomach .i 299 to 805 1 to 507       507/507
(100 %)
2 diff
(99.7 %id)
BM838414 lymph node, stomach .i 299 to 825 1 to 527       527/527
(100 %)
0 diff
(100 %id)
BF115257 fibrotheoma, ovary .i 300 to 961 663 to 1       663/679
(97 %)
20 diff
(97.1 %id)
CN266488 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 303 to 870 1 to 568       568/568
(100 %)
0 diff
(100 %id)
CN266473 embryonic stem cells, DMSO-treated H9 cellline .i 306 to 953 1 to 648       648/654
(99 %)
1 diff
(99.9 %id)
CN266353 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .i 310 to 820 1 to 510       510/510
(100 %)
2 diff
(99.7 %id)
CN266359 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .i 312 to 984 1 to 672   AAA   672/672
(100 %)
1 diff
(99.9 %id)
CN266407 embryonic stem cells, DMSO-treated H9 cellline .i 312 to 822 9 to 519       511/519
(98 %)
7 diff
(98.7 %id)
BM796911 Ascites, stomach .i 313 to 736 1 to 424       424/424
(100 %)
1 diff
(99.8 %id)
BU682125 lung .i 313 to 959 660 to 19   AAA   642/645
(99 %)
6 diff
(99.1 %id)
CN266394 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 321 to 959 1 to 639       639/639
(100 %)
0 diff
(100 %id)
AW170322 cervix, tumor .i 322 to 958 636 to 1       636/647
(98 %)
44 diff
(93.2 %id)
AA873153 2 pooled tumors (clear cell type), Kidney .i 324 to 961 633 to 2       632/633
(99 %)
15 diff
(97.7 %id)
BQ361351 ovary .i 326 to 817 493 to 2       492/495
(99 %)
23 diff
(95.4 %id)
AA340693 Kidney .i 327 to 669 1 to 343       343/343
(100 %)
0 diff
(100 %id)
AW167930 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 329 to 959 629 to 1       629/629
(100 %)
14 diff
(97.8 %id)
CN266388 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 331 to 721 1 to 391       391/391
(100 %)
1 diff
(99.8 %id)
BI524893 pooled lung and spleen .i 331 to 896 590 to 13       578/809
(71 %)
25 diff
(97.0 %id)
TI_44159954   .i 331 to 896 590 to 13       578/809
(71 %)
25 diff
(97.0 %id)
CN266377 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 333 to 872 1 to 540       540/540
(100 %)
1 diff
(99.9 %id)
AI814898 adenocarcinoma, Pancreas .i 336 to 961 624 to 1       624/624
(100 %)
9 diff
(98.6 %id)
TI_154034498   .i 342 to 948 712 to 111   AAA   602/751
(80 %)
6 diff
(99.3 %id)
BM009733 amelanotic melanoma, cell line, skin .i 346 to 959 1 to 615   AAA   615/615
(100 %)
3 diff
(99.6 %id)
BM010630 amelanotic melanoma, cell line, skin .i 346 to 961 1 to 616       616/634
(97 %)
4 diff
(99.4 %id)
AW966037   .i 347 to 959 613 to 1     Submitted on the opposite strand 613/613
(100 %)
4 diff
(99.4 %id)
BM553786 amelanotic melanoma, cell line, skin .i 347 to 922 28 to 607       580/1177
(49 %)
25 diff
(97.9 %id)
TI_59384503   .i 347 to 959 63 to 676   AAA   614/614
(100 %)
2 diff
(99.7 %id)
TI_59385467   .i 347 to 961 59 to 673       615/772
(79 %)
3 diff
(99.7 %id)
CN266443 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 348 to 958 1 to 611       611/611
(100 %)
1 diff
(99.9 %id)
BM971789 lung .i 349 to 959 627 to 19   AAA   609/609
(100 %)
2 diff
(99.7 %id)
BU185981 epidermoid carcinoma, cell line, salivary gland .i 350 to 982 674 to 35   AAA Submitted on the opposite strand 640/955
(67 %)
16 diff
(98.4 %id)
AI672867 colon, colonic mucosa from 3 patients with Crohn'sdisease .i 357 to 961 608 to 2       607/608
(99 %)
26 diff
(95.8 %id)
BF058749 fibrotheoma, ovary .i 358 to 959 602 to 1       602/602
(100 %)
2 diff
(99.7 %id)
BU680894 lung .i 358 to 959 619 to 19   AAA   601/601
(100 %)
2 diff
(99.7 %id)
AA905511 pooled .i 359 to 961 602 to 3       600/602
(99 %)
23 diff
(96.2 %id)
BM984753 lung .i 359 to 959 620 to 19   AAA   602/602
(100 %)
8 diff
(98.7 %id)
BM998538 lung, Metastatic Chondrosarcoma .i 360 to 959 617 to 19   AAA   599/599
(100 %)
2 diff
(99.7 %id)
BF799608 colon_ins .i 364 to 706 345 to 1     Submitted on the opposite strand 345/345
(100 %)
9 diff
(97.4 %id)
BQ021188 lung, Metastatic Chondrosarcoma .i 365 to 959 613 to 19   AAA   595/595
(100 %)
0 diff
(100 %id)
AI653634 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus .i 366 to 959 604 to 14   AAA   591/591
(100 %)
7 diff
(98.9 %id)
CN266491 embryonic stem cells, DMSO-treated H9 cellline .i 368 to 805 1 to 438       438/438
(100 %)
2 diff
(99.6 %id)
AA837515 epithelium (cell line), Prostate .i 369 to 959 617 to 33   AAA   585/585
(100 %)
43 diff
(92.7 %id)
BI711129 insulinoma, Pancreas .i 370 to 959 605 to 16   AAA   590/590
(100 %)
2 diff
(99.7 %id)
AA670096 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .i 377 to 911 1 to 532       532/532
(100 %)
9 diff
(98.4 %id)
AA773276 mixed (see below), Pooled human melanocyte, fetal heart, andpregnant uterus .i 377 to 946 1 to 562       562/569
(98 %)
63 diff
(89.0 %id)
BQ706596 Spleen .i 384 to 959 1 to 576   AAA   576/576
(100 %)
0 diff
(100 %id)
AW073723 2 pooled high-grade transitional celltumors, genitourinary tract .i 385 to 966 583 to 4       580/583
(99 %)
13 diff
(97.8 %id)
CN266476 embryonic stem cells, cell lines H1, H7, andH9 .i 392 to 956 565 to 1     Submitted on the opposite strand 565/565
(100 %)
0 diff
(100 %id)
BQ361199 ovary .i 405 to 811 1 to 405       405/405
(100 %)
7 diff
(98.3 %id)
AA565888 colon, tumor .i 407 to 959 545 to 1       545/545
(100 %)
11 diff
(98.0 %id)
AA581813 germ cell tumor .i 407 to 961 553 to 1       553/556
(99 %)
6 diff
(99.0 %id)
AA622740 breast .i 407 to 941 530 to 1       530/530
(100 %)
32 diff
(94.0 %id)
AA657525   .i 412 to 959 556 to 12   AAA   545/545
(100 %)
14 diff
(97.5 %id)
BE271931 adenocarcinoma cell line, ovary .i 418 to 964 1 to 553       553/775
(71 %)
15 diff
(98.1 %id)
AI675942 Prostate .i 419 to 961 544 to 2       543/544
(99 %)
1 diff
(99.9 %id)
AA947686 carcinoid, lung .i 424 to 961 539 to 1       539/539
(100 %)
20 diff
(96.3 %id)
AW439343 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 434 to 959 538 to 12   AAA   527/527
(100 %)
4 diff
(99.3 %id)
AA677118 liver and spleen .i 436 to 959 518 to 2       517/518
(99 %)
10 diff
(98.1 %id)
BU737371 eye, fetal eyes .i 436 to 959 541 to 18   fully sequenced, AAA   524/524
(100 %)
0 diff
(100 %id)
BE765150 nervous_tumor .i 438 to 721 284 to 1       284/287
(98 %)
3 diff
(99.0 %id)
AA095763   .i 459 to 715 1 to 255       255/266
(95 %)
8 diff
(97.0 %id)
AA834416 adenocarcinoma, colon .i 464 to 784 321 to 1       321/334
(96 %)
14 diff
(95.9 %id)
AA244008   .i 465 to 910 13 to 449       437/449
(97 %)
17 diff
(96.3 %id)
AA856700 pharynx, squamous cell carcinoma .i 465 to 961 486 to 1       486/487
(99 %)
17 diff
(96.6 %id)
AI349513 lung .i 465 to 961 505 to 3       503/527
(95 %)
12 diff
(97.8 %id)
AW243736 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 465 to 961 495 to 1       495/499
(99 %)
15 diff
(97.0 %id)
AA857612 epithelium (cell line), Prostate .i 467 to 957 487 to 1       487/487
(100 %)
11 diff
(97.8 %id)
AI288014 Kidney, renal cell tumor .i 467 to 959 518 to 31   AAA   488/489
(99 %)
14 diff
(97.2 %id)
CA443585 lung, Metastatic Chondrosarcoma .i 467 to 959 509 to 19   AAA   491/491
(100 %)
4 diff
(99.2 %id)
AA092202   .i 473 to 663 1 to 190       190/190
(100 %)
4 diff
(97.9 %id)
W25583 lung .i 473 to 681 1 to 213   fully sequenced,   213/213
(100 %)
0 diff
(100 %id)
BM708882 eye, RPE and Choroid .i 473 to 966 1 to 493       493/494
(99 %)
3 diff
(99.4 %id)
AI564903 anaplastic oligodendroglioma, brain .i 475 to 870 402 to 1       402/453
(88 %)
20 diff
(95.6 %id)
BF036720 adenocarcinoma, ovary .i 475 to 959 1 to 487   AAA   487/487
(100 %)
2 diff
(99.6 %id)
BM697652 eye, fetal eyes .i 480 to 959 1 to 480   AAA   480/480
(100 %)
0 diff
(100 %id)
AA605069 adrenal adenoma, adrenal gland .i 482 to 959 477 to 1       477/477
(100 %)
4 diff
(99.2 %id)
W76149 heart .i 487 to 946 1 to 463       463/463
(100 %)
8 diff
(98.3 %id)
BF155224 breast .i 494 to 816 357 to 30       328/366
(89 %)
4 diff
(99.0 %id)
BF155259 breast .i 494 to 816 18 to 338       321/349
(91 %)
7 diff
(98.0 %id)
BF743525 breast .i 494 to 816 18 to 348       331/357
(92 %)
8 diff
(97.8 %id)
BF743584 breast .i 494 to 816 12 to 335       324/360
(90 %)
8 diff
(97.8 %id)
BF743597 breast .i 494 to 815 335 to 13     Submitted on the opposite strand 323/346
(93 %)
0 diff
(100 %id)
CN266363 embryonic stem cells, embryoid bodiesderived from H1, H7 and H9 cells .i 495 to 959 20 to 484   AAA   465/484
(96 %)
8 diff
(98.4 %id)
BF761628 colon_est .i 497 to 816 1 to 321       321/327
(98 %)
3 diff
(99.1 %id)
AI350498 pooled germ cell tumors .i 497 to 961 465 to 1       465/465
(100 %)
5 diff
(99.0 %id)
AW473570 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 497 to 966 476 to 6       471/476
(98 %)
9 diff
(98.2 %id)
AI354687 lung .i 498 to 960 463 to 1       463/463
(100 %)
1 diff
(99.8 %id)
DB567247 hypothalamus .i 502 to 959 1 to 458     Submitted on the opposite strand 458/458
(100 %)
0 diff
(100 %id)
BF743523 breast .i 503 to 822 44 to 366       323/370
(87 %)
19 diff
(94.9 %id)
BE350678 2 pooled Wilms' tumors, one primary and onemetastatic to brain, Kidney .i 505 to 959 466 to 12   AAA   455/559
(81 %)
25 diff
(95.6 %id)
CN266414 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 506 to 959 1 to 454   AAA   454/454
(100 %)
3 diff
(99.4 %id)
AI344761 2 pooled tumors (clear cell type), Kidney .i 506 to 961 458 to 3       456/458
(99 %)
0 diff
(100 %id)
AI351481   .i 506 to 915 413 to 1       413/417
(99 %)
16 diff
(96.2 %id)
AI546836 Prostate .i 507 to 966 1 to 463       463/475
(97 %)
12 diff
(97.5 %id)
AI546843 Prostate .i 507 to 966 1 to 464       464/714
(64 %)
7 diff
(99.1 %id)
CN266405 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 507 to 966 1 to 460       460/463
(99 %)
16 diff
(96.6 %id)
CN266381 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 510 to 959 8 to 457   AAA   450/457
(98 %)
6 diff
(98.7 %id)
AV699411 hepatocellular carcinoma .i 510 to 953 444 to 1       444/651
(68 %)
6 diff
(99.1 %id)
AV700357.
matches multiple genes
hepatocellular carcinoma .i 510 to 938 429 to 1     also hits gene DOM3Z 429/643
(66 %)
1 diff
(99.9 %id)
AV698390 hepatocellular carcinoma .i 511 to 900 1 to 384       384/384
(100 %)
5 diff
(98.7 %id)
AI363381 brain, glioblastoma (pooled) .i 515 to 961 449 to 3       447/449
(99 %)
2 diff
(99.6 %id)
AW182617 cervix, tumor .i 516 to 958 443 to 1       443/443
(100 %)
2 diff
(99.6 %id)
BM688870 eye, eye anterior segment .i 516 to 960 9 to 453       445/453
(98 %)
6 diff
(98.7 %id)
AA063086 pineal gland .i 521 to 960 447 to 1       447/447
(100 %)
13 diff
(97.1 %id)
AA330721 embryo .i 522 to 700 1 to 179       179/179
(100 %)
0 diff
(100 %id)
BE694608 breast .i 527 to 797 275 to 7       269/275
(97 %)
1 diff
(99.7 %id)
AI283102 placenta .i 527 to 961 436 to 2       435/436
(99 %)
0 diff
(100 %id)
CN266463 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 529 to 959 3 to 433   AAA   431/433
(99 %)
6 diff
(98.7 %id)
AI560969 anaplastic oligodendroglioma, brain .i 533 to 966 436 to 3       434/436
(99 %)
0 diff
(100 %id)
BG110190 Bone, osteosarcoma, cell line .i 535 to 959 1 to 425   AAA   425/425
(100 %)
0 diff
(100 %id)
AI904529 breast .i 539 to 866 330 to 3       328/332
(98 %)
1 diff
(99.7 %id)
AI243590 pooled .i 542 to 958 416 to 1       416/422
(98 %)
7 diff
(98.4 %id)
BQ029211 lung, Metastatic Chondrosarcoma .i 543 to 959 435 to 19   AAA   417/417
(100 %)
0 diff
(100 %id)
AA092613   .i 545 to 868 1 to 316       316/319
(99 %)
10 diff
(96.9 %id)
AA554302 colon .i 547 to 959 413 to 1       413/413
(100 %)
1 diff
(99.8 %id)
AI653485 ovary, tumor, 5 pooled (see description) .i 549 to 959 411 to 1       411/415
(99 %)
0 diff
(100 %id)
CN266371 embryonic stem cells, DMSO-treated H9 cellline .i 550 to 858 1 to 309       309/309
(100 %)
4 diff
(98.8 %id)
AA968896 Kidney, kidney tumor .i 550 to 959 445 to 36   AAA   410/410
(100 %)
1 diff
(99.8 %id)
AA160689 Pancreas .i 556 to 989 432 to 1       432/432
(100 %)
5 diff
(98.9 %id)
AI354641 poorly differentiated adenocarcinoma withsignet ring cell features, stomach .i 558 to 959 403 to 1       403/403
(100 %)
3 diff
(99.3 %id)
AI358308 moderately-differentiated endometrialadenocarcinoma, 3 pooled tumors, uterus .i 562 to 961 399 to 2       398/399
(99 %)
6 diff
(98.5 %id)
AA569487   .i 567 to 959 408 to 16   AAA   393/393
(100 %)
5 diff
(98.8 %id)
AA775927   .i 570 to 959 391 to 1       391/391
(100 %)
9 diff
(97.7 %id)
CN266344 embryonic stem cells, DMSO-treated H9 cellline .i 573 to 960 1 to 388   AAA   388/388
(100 %)
2 diff
(99.5 %id)
AA090244   .i 575 to 961 1 to 373       373/374
(99 %)
19 diff
(95.0 %id)
AI302461 2 pooled tumors (clear cell type), Kidney .i 576 to 959 382 to 1       382/382
(100 %)
3 diff
(99.3 %id)
W19684 parathyroid gland, parathyroid tumor .i 578 to 829 1 to 252   fully sequenced,   252/252
(100 %)
4 diff
(98.5 %id)
BP242527 Liver .i 579 to 960 1 to 382       382/386
(98 %)
4 diff
(99.0 %id)
BG960321 colon .i 581 to 713 1 to 134       134/134
(100 %)
9 diff
(93.3 %id)
BF330544 breast_normal .i 585 to 795 30 to 240       211/240
(87 %)
7 diff
(97.1 %id)
AA650016 normal prostate, Prostate .i 589 to 959 370 to 1       370/370
(100 %)
4 diff
(99.0 %id)
CN266445 embryonic stem cells, DMSO-treated H9 cellline .i 590 to 956 133 to 499       367/499
(73 %)
6 diff
(98.8 %id)
N88126   .i 590 to 874 1 to 280       280/282
(99 %)
14 diff
(95.1 %id)
BQ267839 insulinoma, Pancreas .i 598 to 959 379 to 18   fully sequenced, AAA   362/362
(100 %)
0 diff
(100 %id)
BQ267523 insulinoma, Pancreas .i 610 to 959 1 to 350   AAA   350/350
(100 %)
4 diff
(98.9 %id)
BQ272218 insulinoma, Pancreas .i 615 to 959 362 to 18   AAA   345/349
(98 %)
0 diff
(100 %id)
CK905930 insulinoma, Pancreas .i 615 to 959 361 to 17   AAA   345/349
(98 %)
1 diff
(99.8 %id)
AA550916 normal prostatic epithelial cells, Prostate .i 616 to 959 365 to 22   AAA   344/344
(100 %)
13 diff
(96.3 %id)
AI972309 Prostate .i 617 to 913 297 to 1       297/297
(100 %)
3 diff
(99.0 %id)
BI497291 cochlea, ear .i 623 to 962 1 to 340   AAA   340/340
(100 %)
5 diff
(98.6 %id)
AI869410 uterus, well-differentiated endometrialadenocarcinoma, 7 pooled tumors .i 624 to 960 336 to 1       336/380
(88 %)
12 diff
(96.9 %id)
AA126065   .i 626 to 991 368 to 1   fully sequenced,   368/368
(100 %)
7 diff
(98.1 %id)
AL520795 brain, neuroblastoma cells, Neuroblastoma Cot 10-normalized .i 627 to 990 1 to 363       363/364
(99 %)
2 diff
(99.5 %id)
H99387 melanocyte .i 627 to 959 337 to 1       337/460
(73 %)
10 diff
(97.9 %id)
AA885582 carcinoid, lung .i 627 to 961 335 to 2       334/339
(98 %)
0 diff
(100 %id)
AI051519   .i 627 to 961 336 to 3       334/336
(99 %)
0 diff
(100 %id)
AI363998 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 627 to 959 356 to 25   AAA   332/443
(74 %)
8 diff
(98.2 %id)
AI689031 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 627 to 959 376 to 47   AAA   330/367
(89 %)
28 diff
(92.4 %id)
BE866790 adenocarcinoma, colon .i 627 to 954 1 to 328       328/328
(100 %)
0 diff
(100 %id)
AA155767 Pancreas .i 629 to 966 341 to 2       340/373
(91 %)
0 diff
(100 %id)
BQ304538 breast .i 630 to 816 24 to 219       196/228
(85 %)
10 diff
(95.7 %id)
AA065174   .i 644 to 953 1 to 311       311/311
(100 %)
3 diff
(99.1 %id)
AA659174   .i 644 to 984 8 to 347   AAA   340/347
(97 %)
6 diff
(98.3 %id)
AA687198   .i 644 to 984 8 to 347   AAA   340/347
(97 %)
6 diff
(98.3 %id)
T28360 colon, epididymis .i 646 to 894 1 to 249       249/249
(100 %)
1 diff
(99.6 %id)
AA921901 pooled .i 648 to 961 314 to 1       314/314
(100 %)
3 diff
(99.1 %id)
AA635808 normal prostate, Prostate .i 650 to 959 309 to 1       309/309
(100 %)
5 diff
(98.4 %id)
N92857 lung .i 651 to 959 308 to 1   fully sequenced,   308/308
(100 %)
3 diff
(99.1 %id)
AI970995 Prostate .i 654 to 961 308 to 1       308/308
(100 %)
1 diff
(99.7 %id)
AI494596 anaplastic oligodendroglioma, brain .i 656 to 997 360 to 19   tiling clone, AAA   342/342
(100 %)
0 diff
(100 %id)
AI784469 anaplastic oligodendroglioma, brain .i 658 to 966 310 to 2       309/310
(99 %)
0 diff
(100 %id)
AI566999 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 658 to 960 310 to 1       310/310
(100 %)
7 diff
(97.8 %id)
AW170212 cervix .i 658 to 959 313 to 12   AAA   302/302
(100 %)
18 diff
(94.1 %id)
AA928381 pooled germ cell tumors .i 664 to 958 300 to 6       295/300
(98 %)
0 diff
(100 %id)
AI868371 pooled .i 667 to 959 320 to 31   AAA   290/290
(100 %)
20 diff
(93.2 %id)
CB854816 lung .i 671 to 896 226 to 1       226/226
(100 %)
4 diff
(98.3 %id)
CD251371 brain, Pituitary .i 673 to 959 1 to 287   AAA   287/287
(100 %)
0 diff
(100 %id)
CN266434 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 678 to 960 1 to 283   AAA   283/283
(100 %)
1 diff
(99.7 %id)
AW150636 serous papillary carcinoma, high grade, 2pooled tumors, uterus .i 684 to 961 283 to 5       279/283
(98 %)
0 diff
(100 %id)
AV702749 adrenal gland .i 687 to 959 1 to 272   AAA   272/272
(100 %)
3 diff
(98.9 %id)
AW366864 head_neck .i 698 to 858 164 to 4       161/165
(97 %)
0 diff
(100 %id)
T54666 fetal spleen, Spleen .i 704 to 961 261 to 4       258/261
(98 %)
0 diff
(100 %id)
AI924384 lung, squamous cell carcinoma, poorlydifferentiated (4 pooled tumors, including primary andmetastatic) .i 704 to 965 262 to 1       262/262
(100 %)
6 diff
(97.8 %id)
C18016 placenta .i 706 to 959 1 to 254       254/254
(100 %)
0 diff
(100 %id)
BF114899 fibrotheoma, ovary .i 707 to 959 270 to 18   AAA   253/253
(100 %)
2 diff
(99.3 %id)
AA525365 prostate metastasis, liver .i 709 to 959 1 to 251   AAA   251/251
(100 %)
5 diff
(98.1 %id)
AI784640 uterus .i 709 to 960 253 to 1       253/253
(100 %)
1 diff
(99.7 %id)
AI758612 poorly-differentiated endometrialadenocarcinoma, 2 pooled tumors, uterus .i 709 to 959 270 to 19   AAA   252/253
(99 %)
2 diff
(99.3 %id)
AA528748 Kidney .i 732 to 959 7 to 234   AAA   228/234
(97 %)
6 diff
(97.5 %id)
CN266386 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 734 to 959 1 to 226   AAA   226/226
(100 %)
0 diff
(100 %id)
BF063999 colon, colon tumor, RER+ .i 737 to 952 224 to 7       218/224
(97 %)
0 diff
(100 %id)
BE832973 ovary .i 761 to 891 134 to 5       130/134
(97 %)
0 diff
(100 %id)
AA612817 colon, colon tumor RER+ .i 777 to 961 187 to 2       186/187
(99 %)
0 diff
(100 %id)
BG153008 head/neck, nasopharyngeal carcinoma .i 777 to 961 56 to 240       185/244
(75 %)
2 diff
(99.2 %id)
BG055557 normal head/neck tissue .i 777 to 961 56 to 240       185/244
(75 %)
1 diff
(99.6 %id)
BG222691 head/neck, nasopharyngeal carcinoma .i 789 to 961 179 to 5       175/179
(97 %)
0 diff
(100 %id)
AW496797   .i 792 to 888 97 to 1       97/98
(98 %)
1 diff
(99.0 %id)
AA292397 ovarian tumor, ovary .i 792 to 941 1 to 150   fully sequenced,   150/150
(100 %)
0 diff
(100 %id)
AA402706.
matches multiple genes
ovarian tumor, ovary .i 792 to 941 1 to 150     also hits gene WDR13 150/150
(100 %)
0 diff
(100 %id)
BF434087 fibrotheoma, ovary .i 794 to 966 173 to 2       172/173
(99 %)
0 diff
(100 %id)
N90030 parathyroid gland, parathyroid tumor .i 799 to 959 173 to 13   fully sequenced, AAA   161/161
(100 %)
0 diff
(100 %id)
AI699968 pooled germ cell tumors .i 813 to 959 161 to 15   AAA   147/147
(100 %)
0 diff
(100 %id)
AA402271.
matches multiple genes
ovarian tumor, ovary .i 826 to 959 134 to 1     also hits gene CSNK1E 134/134
(100 %)
0 diff
(100 %id)
AA720944 synovial sarcoma .i 830 to 959 130 to 1       130/130
(100 %)
0 diff
(100 %id)
CB410405 maxilla, pooled .i 831 to 959 1 to 129   AAA   129/129
(100 %)
0 diff
(100 %id)
CB409504 maxilla, pooled .i 831 to 959 1 to 129   AAA   129/129
(100 %)
0 diff
(100 %id)
CD523192 pooled .i 832 to 963 1 to 132   AAA   132/132
(100 %)
1 diff
(99.3 %id)
AI633889 pooled germ cell tumors .i 865 to 959 116 to 22   AAA   95/95
(100 %)
0 diff
(100 %id)
AI989937 pooled germ cell tumors .i 865 to 959 114 to 20   AAA   95/95
(100 %)
2 diff
(97.9 %id)
AA236707 ovarian tumor, ovary .i 866 to 959 94 to 1   fully sequenced,   94/94
(100 %)
0 diff
(100 %id)
CN266428 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .i 868 to 959 1 to 92   AAA   92/92
(100 %)
4 diff
(95.7 %id)
CD520380 pooled .i 868 to 991 1 to 124   AAA   124/124
(100 %)
7 diff
(94.4 %id)
TI_57244537   .j 1 to 776 35 to 809 N113K A114C Q115S C116V Q117P ...     782/809
(96 %)
7 diff
(99.2 %id)
BI915189 brain .j 2 to 776 1 to 775 N113K A114C Q115S C116V Q117P ... tiling clone,   775/775
(100 %)
2 diff
(99.8 %id)
CN266352 embryonic stem cells, cell lines H1, H7, andH9 .j 14 to 483 9 to 481       473/481
(98 %)
7 diff
(98.6 %id)
BQ921047 epidermoid carcinoma, cell line, lung .j 18 to 680 1 to 668       668/980
(68 %)
18 diff
(98.2 %id)
BP870930 embryonal kidney .j 26 to 359 1 to 334       334/334
(100 %)
1 diff
(99.8 %id)
BQ426079 leiomyosarcoma, uterus .j 27 to 754 1 to 729       729/876
(83 %)
8 diff
(99.1 %id)
DR763258 embryonic stem .j 27 to 126 1 to 100       100/100
(100 %)
2 diff
(98.0 %id)
CX870295 embryonic stem .j 40 to 599 1 to 560       560/560
(100 %)
0 diff
(100 %id)
CB214980 normal endometrium, late proliferativephase, cycle day 13, uterus .j 279 to 775 1 to 497 exact tiling clone,   497/497
(100 %)
0 diff
(100 %id)
CN266354 embryonic stem cell, retinoic acid andmitogen-treated hES cell line H7 .k 1 to 498 1 to 498 exact tiling clone,   498/498
(100 %)
0 diff
(100 %id)
DQ323888   .l 1 to 685 1 to 684 exact tiling clone, AAA   684/684
(100 %)
1 diff
(99.9 %id)
AW371105 breast Gene MDK, variant not shown         This clone was ignored    
BG987929 head_neck Gene MDK, variant not shown         This clone was ignored    
CN266433 embryonic stem cells, DMSO-treated H9 cellline Gene MDK, variant not shown         Suspected internal deletion, this clone was ignored    
CN278543 embryonic stem cells, DMSO-treated H9 cellline Gene MDK, variant not shown         Suspected internal deletion, this clone was ignored    
DQ323889   Gene MDK, variant not shown       AAA Suspected internal deletion, this clone was ignored    
DQ323890   Gene MDK, variant not shown       AAA Suspected internal deletion, this clone was ignored    
BE612522 adenocarcinoma, ovary Gene MDK, variant not shown         Suspected internal deletion, this clone was ignored    
BP371892 umbilical cord Gene MDK, variant not shown       AAA Suspected internal deletion, this clone was ignored    
BP374695 umbilical cord Gene MDK, variant not shown         Suspected internal deletion, this clone was ignored    
? Gene Summary Gene on genome mRNA:.a, .b, .c, .d, .e, .f, .g, .h, .i, .j, .k, .l Alternative mRNAs features, proteins, introns, exons, sequences Expression Tissue Function, regulation, related genes DCI